116 related articles for article (PubMed ID: 12430568)
1. [Imatinib combination therapies--the new CML Study 4].
Helmann R; Berger U; Engelich G
Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
[No Abstract] [Full Text] [Related]
2. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Berger U; Hehlmann R
Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
[No Abstract] [Full Text] [Related]
3. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
4. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.
Johnson-Ansah H; Guilhot J; Rousselot P; Rea D; Legros L; Rigal-Huguet F; Nicolini FE; Mahon FX; Preudhomme C; Guilhot F
Cancer; 2013 Dec; 119(24):4284-9. PubMed ID: 24105694
[TBL] [Abstract][Full Text] [Related]
6. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
Ann Hematol; 2004 Apr; 83(4):258-64. PubMed ID: 14648019
[No Abstract] [Full Text] [Related]
7. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
[TBL] [Abstract][Full Text] [Related]
8. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
9. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Cortes J; Quintás-Cardama A; Jones D; Ravandi F; Garcia-Manero G; Verstovsek S; Koller C; Hiteshew J; Shan J; O'Brien S; Kantarjian H
Cancer; 2011 Feb; 117(3):572-80. PubMed ID: 20886606
[TBL] [Abstract][Full Text] [Related]
10. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
Guilhot F; Druker B; Larson RA; Gathmann I; So C; Waltzman R; O'Brien SG
Haematologica; 2009 Dec; 94(12):1669-75. PubMed ID: 19648168
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
Giles FJ; Shan J; Chen S; Advani SH; Supandiman I; Aziz Z; Caviles AP; Tee GY; Chasen MR; Fahed Z; Chaoj TY; Aydogdu I; Lynott AM
Leuk Lymphoma; 2000 Apr; 37(3-4):367-77. PubMed ID: 10752988
[TBL] [Abstract][Full Text] [Related]
12. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
[TBL] [Abstract][Full Text] [Related]
13. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
[TBL] [Abstract][Full Text] [Related]
14. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T; Burgstaller S; Apfelbeck U; Linkesch W; Seewann H; Fridrik M; Michlmayr G; Krieger O; Lutz D; Lin W; Pont J; Köck L; Abbrederis K; Baldinger C; Buder R; Geissler D; Hausmaninger H; Lang A; Zabernigg A; Duba C; Hilbe W; Eisterer W; Fiegl M; Greil R; Gastl G; Thaler J;
Leuk Res; 2003 May; 27(5):405-11. PubMed ID: 12620292
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Deenik W; van der Holt B; Verhoef GE; Smit WM; Kersten MJ; Kluin-Nelemans HC; Verdonck LF; Ferrant A; Schattenberg AV; Janssen JJ; Sonneveld P; van Marwijk Kooy M; Wittebol S; Willemze R; Wijermans PW; Westveer PH; Beverloo HB; Valk P; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
Blood; 2008 Mar; 111(5):2581-8. PubMed ID: 18172005
[TBL] [Abstract][Full Text] [Related]
16. Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
Morgensztern D; Rosado MF; Raez LE; Santos ES; Cassileth PA
Leuk Lymphoma; 2005 Feb; 46(2):297-8. PubMed ID: 15621818
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
Hahn EA; Glendenning GA; Sorensen MV; Hudgens SA; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Dobrez DG; Hensley ML; Cella D;
J Clin Oncol; 2003 Jun; 21(11):2138-46. PubMed ID: 12775739
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.
Morishima Y; Ogura M; Nishimura M; Yazaki F; Bessho M; Mizoguchi H; Chiba S; Hirai H; Tauchi T; Urabe A; Takahashi M; Ohnishi K; Yokozawa T; Emi N; Hirano M; Shimazaki C; Nakao S; Kawai Y; Fujimoto M; Taguchi H; Jinnai I; Ohno R
Int J Hematol; 2004 Oct; 80(3):261-6. PubMed ID: 15540902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
